Artelo Biosciences presents drug metabolism data for ART26.12 candidate Jun 10, 2026 07:47AM
Artelo Biosciences files $6.5M at-the-market offering prospectus May 26, 2026 04:50PM
Artelo Biosciences terminates at-the-market offering agreement May 15, 2026 04:03PM
Artelo Biosciences (ARTL) files $75M mixed shelf May 4, 2026 04:47PM
Artelo publishes study supporting ART26.12 pain treatment Apr 20, 2026 07:51AM


Apr 7, 2026 04:21PM Artelo Biosciences (ARTL) files for 9.82M share offering by selling stockholders
Mar 25, 2026 07:31AM Artelo Biosciences enters glaucoma market via funded study
Mar 18, 2026 07:43AM Artelo enters glaucoma study agreement with Belfast Health Trust
Feb 24, 2026 08:02AM Artelo Biosciences reports $12.9 million loss for fiscal 2025
Dec 23, 2025 09:00AM Artelo Biosciences comments on presidential executive order for CBD research
Dec 3, 2025 08:30AM Artelo Biosciences publishes study on anxiety treatment compound
Nov 17, 2025 04:58PM Artelo Biosciences (ARTL) files for 900K share offering by selling stockholders
Nov 12, 2025 04:30PM Artelo Biosciences (ARTL) Tops Q3 EPS by 397c
Oct 15, 2025 09:15AM Artelo Biosciences presents clinical data for two drug candidates
Sep 10, 2025 08:32AM Artelo Biosciences publishes preclinical data on ART12.11 compound
Sep 8, 2025 07:05AM D. Boral Capital Downgrades Artelo Biosciences, Inc. (ARTL) to Hold
Aug 25, 2025 07:55AM Artelo Biosciences reports positive food effect data for pain drug
Aug 13, 2025 06:55PM Artelo Biosciences, Inc. (ARTL) Misses Q2 EPS by 548c
Aug 4, 2025 08:07AM D. Boral Capital Reiterates Buy Rating on Artelo Biosciences, Inc. (ARTL)
Jul 9, 2025 07:50AM Artelo Biosciences reports osteoarthritis pain relief data for ART26.12
Jul 8, 2025 07:07AM D. Boral Capital Upgrades Artelo (ARTL) to Buy, 'Reverse Complete'
Jul 7, 2025 07:45AM Artelo presents preclinical data on depression drug candidate ART12.11
Jun 30, 2025 07:45AM Artelo Biosciences (ARTL) Announces Positive First-in-Human Data for ART26.12
Jun 26, 2025 08:02AM Artelo Biosciences (ARTL) Announces $1.425M ATM
Jun 11, 2025 09:57AM D. Boral Capital Downgrades Artelo Biosciences (ARTL) to Hold
Jun 11, 2025 08:30AM Artelo Biosciences (ARTL) Announces 1:6 Reverse Share Split
Jun 5, 2025 09:01AM Artelo's (ARTL) ART26.12 Compares Favorably to Naproxen in an Osteoarthritis Pain Study
May 13, 2025 05:23PM Artelo Biosciences, Inc. (ARTL) Misses Q1 EPS by 59c
Feb 14, 2025 09:00AM Artelo Biosciences (ARTL) Announces New Data on ART12.11 Tablets
Dec 9, 2024 09:15AM Artelo Biosciences (ARTL) Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia
Nov 12, 2024 04:50PM Artelo Biosciences, Inc. (ARTL) Tops Q3 EPS by 44c
Oct 1, 2024 07:15AM EF Hutton Starts Artelo (ARTL) at Buy
Aug 13, 2024 10:29AM Artelo Biosciences, Inc. (ARTL) Tops Q2 EPS by 4c
Jul 15, 2024 08:31AM Artelo Biosciences (ARTL) Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor